By I. Grim. Oberlin College.
Adverse events • In longer-term observational studies modafinil 200 mg fast delivery, dry mouth was the most common adverse event for all the drugs discount modafinil 100 mg with visa. Differences in adverse event profiles between long-acting products and short-acting products are unclear. Overactive bladder Page 14 of 73 Final Report Update 4 Drug Effectiveness Review Project - A short-term head-to-head comparison of tolterodine immediate-release with tolterodine extended-release found a higher rate of dry mouth with the immediate-release form. Withdrawal due to adverse event was similar for both. The difference between drugs based on withdrawals is less clear: 2 trials comparing solifenacin with tolterodine found similar rates of adverse events overall. Subpopulations • Evidence from 5 studies was not consistent in identifying differences between men and women in response to tolterodine. Adverse event profiles were similar to those found in the overall trial populations. Solifenacin was found to have response and adverse event rates in a Hispanic subgroup that were similar to those of the overall trial population in 1 study. Tolterodine extended-release and tolterodine immediate-release were found to be similarly effective in Japanese and Korean women, with fewer adverse events in the tolterodine extended-release group. The Japanese patients were shown to have improved quality of life in both groups; no such analysis was undertaken for the Korean patients. Flavoxate, scopolamine, and hyoscyamine • Head-to-head comparisons with flavoxate were poor quality and there were no head-to- head comparisons of scopolamine, or hyoscyamine to another drug for OAB. Overactive bladder Page 15 of 73 Final Report Update 4 Drug Effectiveness Review Project Detailed Assessment We found no effectiveness trials of drugs for overactive bladder syndrome. The included trials assessed outcome measures related to efficacy and the trials were primarily short (8-12 weeks). Most of the randomized trials had fair internal validity but their applicability to community practice was difficult to determine. The studies generally excluded patients who would have been at risk of serious adverse events from anticholinergic drugs. Most of the treatment and control groups received standard doses of anticholinergic drugs but some studies compared doses at the higher end of the range of one drug with the lower end of the range of another. Of studies that stated their source of funding, all were funded by the pharmaceutical industry and industry employees often served as coauthors. While several fair- and good-quality systematic reviews examined aspects of treating patients with overactive bladder, only a few directly examined the questions posed here. We include the results of only 2 published systematic reviews in the sections below. One is a good- quality 2005 Cochrane review focused on comparing the effects of different anticholinergic drugs for overactive bladder syndrome using randomized controlled trials that compared 1 15 anticholinergic drug to another or 2 different doses of the same drug. The other was a fair- quality systematic review of the differences in tolerability, safety, and efficacy between 16 oxybutynin, tolterodine, trospium, darifenacin, and solifenacin. Both of these reviews have 16 17 15, 16 been updated since their original publications; here we use only the most recent versions. Three other reviews address questions similar to ours but these results are not discussed below because they do not address the question of comparative effectiveness and harms. The first is a 2008 broad systematic review of nonsurgical treatments for urinary incontinence in women. Oxybutynin immediate-release and tolterodine extended-release were compared to placebo, but 18 conclusions could not be drawn about the comparison. Another is more than 5 years old and as 19 a result includes almost exclusively placebo-controlled trials. Finally, a systematic review of anticholinergic drugs in patients with lower urinary tract symptoms suggestive of overactive 20 bladder and bladder outlet obstruction includes drugs and study designs not included here. For adult patients with urinary urge incontinence/overactive bladder, do anticholinergic drugs differ in effectiveness? We found 28 head-to-head trials of oxybutynin, tolterodine, trospium, flavoxate, solifenacin, 21-48 and/or darifenacin. All included studies and their respective post hoc analyses are summarized in Evidence Table 1. Quality assessments of the studies are presented in Evidence Table 2. One study comparing oxybutynin immediate-release 33 and tolterodine immediate-release, 2 studies comparing oxybutynin immediate- and extended- 41, 42 40, 48 release, and the only 2 flavoxate studies were assessed as poor-quality, and all others were fair-quality. The poor-quality studies suffered from lack of detail about randomization, allocation concealment, and baseline characteristics; lack of randomization; and differences in potentially important baseline characteristics.
Clinical predictors for American College of Chest Physicians Evidence-Based Clini- fatal pulmonary embolism in 15 buy discount modafinil 100mg,520 patients with venous cal Practice Guidelines cheap 200mg modafinil overnight delivery. Heijboer H, Jongbloets LMM, Buller HR, Lensing AWA, ten Circulation. Clinical utility of real-time compression ultrasonogra- 4. An essay towards solving a problem in the doctrine of 21. Does this combining clinical probability, D-dimer testing, and computed patient have deep vein thrombosis? Comparison of the Wells score graphic pulmonary angiography vs ventilation-perfusion lung with the simpliﬁed revised Geneva score for assessing pretest scanning in patients with suspected pulmonary embolism: a probability of pulmonary embolism. Assessment of pretest and heparin compared with acenocoumarol alone in the initial probability of pulmonary embolism in the emergency depart- treatment of proximal-vein thrombosis. The weight heparins versus adjusted dose unfractionated heparin for interobserver reliability of pretest probability assessment in venous thromboembolism. Clinical gestalt twice daily LMWH for the initial treatment of venous thrombo- and the diagnosis of pulmonary embolism: does experience embolism. Van Es J, Douma RA, Mos IC, Huisman MV, Kamphuisen PW. Diagnostic for outpatient treatment of deep venous thrombosis and pulmo- accuracy of D-dimer test for exclusion of venous thromboembo- nary embolism with low-molecular-weight heparin. Safety of outpatient low-intensity warfarin therapy for the prevention of recurrent treatment in acute pulmonary embolism. VTE, thrombophilia, inpatient treatment for patients with acute pulmonary embo- antithrombotic therapy, and pregnancy: Antithrombotic Therapy lism: an international, open-label, randomised, non-inferiority and Prevention of Thrombosis, 9th ed: American College of trial. Chest Physicians Evidence-Based Clinical Practice Guidelines. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger Thrombosis, 9th ed: American College of Chest Physicians M. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Anticardiolipin Heparin plus alteplase compared with heparin alone in patients antibodies predict early recurrence of thromboembolism and with submassive pulmonary embolism. Decousus H, Barral F-G, Buchmuller-Cordier A, et al. A comparison of two year follow-up of patients with permanent vena cava ﬁlters in intensities of warfarin for the prevention of recurrent thrombo- the prevention of pulmonary embolism: the PREPIC (Preven- sis in patients with the antiphospholipid antibody syndrome. Abstract: A multicentre low-intensity warfarin therapy with conventional-intensity war- randomized placebo controlled trial of compression stockings farin therapy for long-term prevention of recurrent venous to prevent the post thrombotic syndrome after proximal deep thromboembolism. Therefore, the duration of anticoagulation therapy after a ﬁrst VTE should be tailored to the estimated risk for recurrence. Anticoagulant therapy should be discontinued after the initial 3 to 6 months in those patients who had the ﬁrst episode in association with temporary risk factors. The duration of anticoagulant therapy in patients who had a ﬁrst episode of cancer-associated VTE should be reassessed over time based on the persistence of cancer and anticancer therapy. After 3 to 6 months of anticoagulant treatment for VTE, patients with a ﬁrst unprovoked event and an estimated low risk for bleeding complications should be evaluated for indeﬁnite treatment on an individualized basis. New oral anticoagulants have been evaluated for the extended treatment of VTE. Large phase 3 studies have shown that dabigatran, rivaroxaban, and apixaban are effective and safe in this indication. These agents do not require monitoring for dose adjustment and could make extended treatment more feasible and acceptable to patients. Introduction limitations of VKAs have been developed recently. The annual incidence of VTE is 1 to 2 cases per 1000 persons in the general Extended treatment of VTE population. Observational studies have shown a recurrence rate associated with an unacceptably high rate of recurrent VTE after of 30% at 10 years after the ﬁrst VTE event if anticoagulation is treatment discontinuation. Randomized studies incidence of recurrent VTE was 8. In these patients, prolonged or indeﬁnite anticoagu- and 4 1 per 1000 patient-days at 5 and 10 years. The long-term lation is not intended to be life-long, but rather a treatment the case-fatality rates were 19%, 25%, and 30% at 1, 2, and 3 years after duration of which will be periodically reassessed based on the the acute event, respectively. Current guidelines suggest indeﬁnite anticoagulation for patients at particularly high risk for recurrent VTE. Risk factors for recurrent VTE with relative strength of with surgery or trauma-associated VTE (HR 0. The main aim of this approach is to identify those patients with unprovoked VTE who could beneﬁt from VTE seems to decline over time, neither the incidence nor the extended anticoagulant treatment.
9 of 10 - Review by I. Grim
Votes: 79 votes
Total customer reviews: 79